CCCC Q4 2022 Earnings — C4 Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CCCCC4 Therapeutics, Inc.

$243M

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M-85.8% YoY

Gross Profit

-$28M-974.0% margin

Operating Income

-$38M-1341.7% margin

Net Income

-$37M-1302.9% margin

EPS (Diluted)

$-0.74

QoQ Revenue Growth

-57.7%

Cash Flow

Operating Cash Flow

-$29M

Free Cash Flow

-$31M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$431M

Total Liabilities

$142M

Stockholders' Equity

$289M

Cash & Equivalents

$30M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$20M	-85.8%
Gross Profit	-$28M	-$6M	-329.4%
Operating Income	-$38M	-$15M	-151.0%
Net Income	-$37M	-$16M	-137.5%